Xenobiotics Triggering Acute Intermittent Porphyria and Their Effect on Mouse Brain Respiratory Complexes
-
Published:2024-02-27
Issue:1
Volume:14
Page:308-319
-
ISSN:2039-4713
-
Container-title:Journal of Xenobiotics
-
language:en
-
Short-container-title:JoX
Author:
Zuccoli Johanna Romina1ORCID, Martínez María del Carmen12, Vallecorsa Pablo3ORCID, Buzaleh Ana María12
Affiliation:
1. Research Center on Porphyrins and Porphyrias (CIPYP)—UBA-CONICET, Hospital of Clinics José de San Martín, Buenos Aires 1120, Argentina 2. Department of Biological Chemistry, Faculty of Exact and Natural Sciences, University of Buenos Aires, Buenos Aires 1428, Argentina 3. National Atomic Energy Commission (CNEA), Buenos Aires 1429, Argentina
Abstract
Heme enzyme dysfunction causes a group of diseases called porphyrias. Particularly, a decrease in porphobilinogen deaminase, involved in the third step of heme biosynthesis, leads to acute intermittent porphyria (AIP). Considering our previous works demonstrating the multiplicity of brain metabolisms affected by porphyrinogenic agents, this study aimed to elucidate whether they cause any alteration on the mitochondrial respiratory chain. The activities of respiratory chain complexes (I to IV) were measured in encephalon mitochondria of CF1 male mice receiving volatile anesthetics: isoflurane (2 mL/kg) and sevoflurane (1.5 mL/kg), ethanol (30%), allylisopropylacetamide (AIA) (350 mg/kg), and barbital (167 mg/kg). Moreover, they were compared versus animals with pathological levels of 5-aminolevulinic acid (ALA, 40 mg/kg). Complex I–III activity was induced by isoflurane and decreased by AIA, ethanol, and ALA. Complex II–III activity was increased by sevoflurane and decreased by isoflurane and AIA. Complex II activity was increased by sevoflurane and barbital and decreased by AIA, ethanol, and ALA. Complex IV activity was increased by barbital and ALA and decreased by sevoflurane. The damage to the respiratory chain by ALA could be reflecting the pathophysiological condition of patients with AIP. Better understanding the broad effect of porphyrinogenic drugs and the mechanisms acting on the onset of AIP is vital in translational medicine.
Funder
CONICET University of Buenos Aires
Reference72 articles.
1. Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias;Ramanujam;Curr. Protoc. Hum. Genet.,2015 2. Heme biosynthesis and the porphyrias;Phillips;Mol. Genet. Metab.,2019 3. The Porphyrias;Muschalek;J. Dtsch. Dermatol. Ges.,2022 4. Cerbino, G., Gerez, E., Varela, L., Melito, V., Parera, V., Batlle, A., and Rossetti, M.V. (2015). Acute Intermittent Porphyria in Argentina. An update. J. Biomed. Biotech., 2015. 5. Ricci, A., Sandri, G., Marcacci, M., Di Pierro, E., Granata, F., Cuoghi, C., Marchini, S., Pietrangelo, A., and Ventura, P. (2021). Endothelial dysfunction in Acute Hepatic Porphyrias. Diagnostics, 12.
|
|